Last reviewed · How we verify
Philadelphia chromosome-positive acute lymphoblastic leukemia
Approved treatments
- Gleevec · M.D. Anderson Cancer Center
- Sprycel · Handa Therap
Sprycel works by blocking the activity of a specific protein called Ephrin type-B receptor 6, which is involved in the growth and survival of cancer cells. - Gleevec · Novartis
Gleevec works by blocking the activity of specific enzymes involved in cancer cell growth and proliferation.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Philadelphia chromosome-positive acute lymphoblastic leukemia patent landscape — cliff calendar, originator estates, attackable patents
- Philadelphia chromosome-positive acute lymphoblastic leukemia treatment landscape brief
- Philadelphia chromosome-positive acute lymphoblastic leukemia treatment updates RSS
Frequently asked questions about Philadelphia chromosome-positive acute lymphoblastic leukemia
What drugs treat Philadelphia chromosome-positive acute lymphoblastic leukemia?
Tracked treatments include Gleevec, Sprycel.
What is the treatment for Philadelphia chromosome-positive acute lymphoblastic leukemia?
Standard treatment for Philadelphia chromosome-positive acute lymphoblastic leukemia includes Gleevec, Sprycel. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Philadelphia chromosome-positive acute lymphoblastic leukemia patent cliff · Philadelphia chromosome-positive acute lymphoblastic leukemia CI report
- Treatment: Gleevec · M.D. Anderson Cancer Center
- Treatment: Sprycel · Handa Therap
- Treatment: Gleevec · Novartis
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing